Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Meagan P. O’Brien; Eduardo Forleo‐Neto; Bret J. Musser; Flonza Isa; Kuo‐Chen Chan; Neena Sarkar; Katharine J. Bar; Ruanne V. Barnabas; Dan H. Barouch; Myron S. Cohen; Christopher B. Hurt; Dale R. Burwen; Mary Marovich; Peijie Hou; Ingeborg Heirman; John D. Davis; K. C. Turner; Divya Ramesh; Adnan Mahmood; Andrea T. Hooper; Jennifer D. Hamilton; Yun‐Ji Kim; Lisa A. Purcell; Alina Baum; Christos A. Kyratsous; James Krainson; Richard Perez-Perez; Rizwana Mohseni; Bari Kowal; A. Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D. Yancopoulos; David M. Weinreich

doi:10.1056/nejmoa2109682

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT04452318.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

O’Brien et al. (2021) studied this question.

synapsesocial.com/papers/69d76666b1cb92dd1bb8ae69 https://doi.org/10.1056/nejmoa2109682

View Full Paper

Ask AI

Bookmark

Share

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Ask about this paper

Abstract

Discussion

Cite This Study

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading